Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M.

Gastroenterology. 2010 Jan;138(1):108-15. doi: 10.1053/j.gastro.2009.08.071. Epub 2009 Sep 18.

PMID:
19766645
2.
3.

Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.

Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):440-50. doi: 10.1016/j.clinre.2013.08.013. Epub 2013 Oct 28. Review.

PMID:
24176812
4.

Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.

Zeuzem S, Poordad F.

Curr Med Res Opin. 2010 Jul;26(7):1733-43. doi: 10.1185/03007995.2010.487038. Review.

PMID:
20482242
5.

Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.

Zeuzem S, Rizzetto M, Ferenci P, Shiffman ML.

Antivir Ther. 2009;14(2):143-54. Review.

PMID:
19430089
6.

Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.

Rumi M, Aghemo A, Prati GM.

J Viral Hepat. 2012 Jan;19 Suppl 1:37-41. doi: 10.1111/j.1365-2893.2011.01525.x. Review.

PMID:
22233412
7.

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.

Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, Sharafi H.

Daru. 2017 Apr 20;25(1):11. doi: 10.1186/s40199-017-0177-x. Review.

8.

Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.

Gluud LL, Marchesini E, Iorio A.

Am J Gastroenterol. 2009 Sep;104(9):2335-41; quiz 2342. doi: 10.1038/ajg.2009.311. Epub 2009 Jun 9. Review.

PMID:
19513022
9.

Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.

Mangia A, Piazzolla V.

Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S179-85. doi: 10.1016/j.dld.2014.09.026. Epub 2014 Oct 31. Review.

10.
11.

Ideal oral combinations to eradicate HCV: The role of ribavirin.

Hézode C, Bronowicki JP.

J Hepatol. 2016 Jan;64(1):215-25. doi: 10.1016/j.jhep.2015.09.009. Epub 2015 Sep 26. Review.

PMID:
26409316
12.
13.

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Slavenburg S, Heijdra YF, Drenth JP.

Dig Dis Sci. 2010 Mar;55(3):579-85. doi: 10.1007/s10620-009-0797-1. Epub 2009 Apr 28. Review.

14.

Treatment of chronic hepatitis C in a slow responder: a case for extended therapy.

Gaglio PJ.

Nat Rev Gastroenterol Hepatol. 2009 Jun;6(6):372-5. doi: 10.1038/nrgastro.2009.65. Review.

PMID:
19494824
15.

Albinterferon-alpha 2b: a new treatment option for hepatitis C.

Flisiak R, Flisiak I.

Expert Opin Biol Ther. 2010 Oct;10(10):1509-15. doi: 10.1517/14712598.2010.521494. Review.

PMID:
20828335
16.

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis.

Peng Q, Li K, Cao MR, Bie CQ, Tang HJ, Tang SH.

Springerplus. 2016 Sep 15;5(1):1569. doi: 10.1186/s40064-016-3218-x. eCollection 2016. Review.

Supplemental Content

Support Center